These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35448196)

  • 1. Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective.
    Ferrario C; Christofides A; Joy AA; Laing K; Gelmon K; Brezden-Masley C
    Curr Oncol; 2022 Apr; 29(4):2720-2734. PubMed ID: 35448196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
    DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
    Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic management of brain metastases in HER2+ breast cancer in 2022.
    Alder L; Sammons S; Van Swearingen AED; Anders CK
    Clin Adv Hematol Oncol; 2022 May; 20(5):325-336. PubMed ID: 35579591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How we treat patients with metastatic HER2-positive breast cancer.
    Nader-Marta G; Martins-Branco D; de Azambuja E
    ESMO Open; 2022 Feb; 7(1):100343. PubMed ID: 34995893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
    Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
    Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023.
    Banys-Paluchowski M; Krawczyk N; Stickeler E; Müller V; Fehm T
    Curr Opin Obstet Gynecol; 2023 Feb; 35(1):54-61. PubMed ID: 36239554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
    Dempsey N; Sandoval A; Mahtani R
    Curr Treat Options Oncol; 2023 Sep; 24(9):1120-1137. PubMed ID: 37428332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.
    Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A
    Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis.
    Ciapponi A; Bardach A; Colaci C; Rodríguez Cairoli F; Argento F; Korbenfeld E; García Martí S
    Rev Peru Med Exp Salud Publica; 2024 May; 41(1):7-18. PubMed ID: 38808848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
    Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L;
    Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
    Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
    ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
    Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
    Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
    Dormann C
    Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
    Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
    JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
    Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
    Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review.
    Lebert J; Lilly EJ
    Curr Oncol; 2022 Apr; 29(4):2539-2549. PubMed ID: 35448182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
    Pourjamal N; Yazdi N; Halme A; Joncour VL; Laakkonen P; Saharinen P; Joensuu H; Barok M
    Clin Exp Metastasis; 2024 Apr; 41(2):91-102. PubMed ID: 38367127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
    Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
    J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
    Moinard-Butot F; Saint-Martin C; Pflumio C; Carton M; Jacot W; Cottu PH; Diéras V; Dalenc F; Goncalves A; Debled M; Patsouris A; Mouret-Reynier MA; Vanlemmens L; Leheurteur M; Emile G; Ferrero JM; Desmoulins I; Uwer L; Eymard JC; Cheaib B; Courtinard C; Bachelot T; Chevrot M; Petit T
    Breast; 2022 Jun; 63():54-60. PubMed ID: 35299035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice.
    Varghese D; Cruz GI; Johanson C; Toland L; Miranda M; Faherty EC; Harland D; Kaplan HG
    Int J Clin Oncol; 2024 Jun; 29(6):780-789. PubMed ID: 38528295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.